losartan has been researched along with gw9662 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K | 1 |
| Chan, LY; Lai, KN; Leung, JC; Tang, SC; Xiao, J | 1 |
| Horiuchi, M; Iwai, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K | 1 |
| Azuma, J; Iekushi, K; Iwabayashi, M; Kusunoki, H; Morishita, R; Okayama, K; Otsu, R; Rakugi, H; Sanada, F; Taniyama, Y | 1 |
| Kobara, M; Nakata, T; Noda, K; Toba, H; Tojo, C; Wang, J | 1 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Shudou, M; Tsukuda, K | 1 |
| Koh, EJ; Lee, SM; Yoon, SJ | 1 |
| Kobara, M; Nakata, T; Ohigashi, M; Toba, H; Wang, J | 1 |
| Baghcheghi, Y; Hosseini, M; Mokhtari-Zaer, A; Moradi-Marjaneh, R; Salmani, H | 1 |
9 other study(ies) available for losartan and gw9662
| Article | Year |
|---|---|
Telmisartan prevented cognitive decline partly due to PPAR-gamma activation.
Topics: Amyloid beta-Peptides; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Benzoates; Brain; Cognition Disorders; Losartan; Male; Mice; Mice, Inbred Strains; PPAR gamma; Telmisartan | 2008 |
Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Blotting, Western; Cells, Cultured; Culture Media, Conditioned; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation; Glomerulonephritis, IGA; Humans; Immunoglobulin A; Intercellular Adhesion Molecule-1; Interleukin-6; Kidney Tubules; Losartan; Male; Mesangial Cells; NF-kappa B; PPAR gamma; Receptor Cross-Talk; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2009 |
Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Benzoates; Blood Flow Velocity; Blood Pressure; Cerebral Cortex; Cytokines; Diabetes Mellitus, Experimental; Drug Antagonism; Drug Therapy, Combination; Infarction, Middle Cerebral Artery; Losartan; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Superoxides; Telmisartan | 2010 |
Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antibodies; Benzimidazoles; Benzoates; Cells, Cultured; Disease Models, Animal; Fibroblasts; Hepatocyte Growth Factor; Hydronephrosis; Kidney; Losartan; Male; Mice; Mice, Knockout; PPAR gamma; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Transforming Growth Factor beta; Ureteral Obstruction | 2012 |
Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta; Benzimidazoles; Benzoates; Blood Urea Nitrogen; Disease Models, Animal; Inflammation; Kidney Failure, Chronic; Losartan; Male; Malondialdehyde; Nephrectomy; PPAR gamma; Rats; Rats, Wistar; Telmisartan; Vasodilation | 2012 |
Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood-Brain Barrier; Blotting, Western; Cognition Disorders; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Losartan; Male; Maze Learning; Mice; Mice, Inbred C57BL; PPAR gamma; Random Allocation; Sensitivity and Specificity; Telmisartan | 2012 |
Losartan protects liver against ischaemia/reperfusion injury through PPAR-γ activation and receptor for advanced glycation end-products down-regulation.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Apoptosis; Cell Nucleus; Cytokines; Dose-Response Relationship, Drug; Down-Regulation; Electrophoretic Mobility Shift Assay; Gene Expression Regulation; Gene Silencing; Liver; Losartan; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; PPAR gamma; Protective Agents; Protein Transport; Random Allocation; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reperfusion Injury | 2013 |
Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta; Benzimidazoles; Benzoates; Blood Pressure; Disease Models, Animal; Drug Partial Agonism; Endothelium, Vascular; Hypertension; Losartan; Male; Nitric Oxide Synthase Type III; PPAR gamma; Rats; Rats, Wistar; Telmisartan; Vasodilation | 2013 |
Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation.
Topics: Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Anilides; Animals; Anxiety; Behavior Rating Scale; Brain-Derived Neurotrophic Factor; Depression; Encephalitis; Hippocampus; Immunity, Innate; Injections, Intraperitoneal; Interleukin-10; Lipopolysaccharides; Losartan; Male; Memory Disorders; Mice; Mice, Inbred BALB C; Oxidative Stress; PPAR gamma | 2020 |